Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PARPinhibit

Financiado

Cerrado

A systems biology approach to tackle PARP inhibitors resistance and identify nov...

A systems biology approach to tackle PARP inhibitors resistance and identify novel therapeutic targets to overcome it Inhibition of PARP1 in cancer therapy is a recently adopted strategy to treat cancers where DNA repair is defective, such as breast and ovarian cancer caused by mutations in BRCA1 or BRCA2. In addition, PARP1 inhibitors (PARPi) ca... ver más

30/12/2023

CNR

251K€

Presupuesto del proyecto: 251K€

Líder del proyecto

CONSIGLIO NAZIONALE DELLE RICERCHE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-12-30

MSCA-IF-2018: Individual Fellowships

I+D

Cerrada hace 6 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

CNR

251.00K€ | Lider

MESUREX

243.40K€ | Participante

SOCIEDAD ANONIMA DE ELECTRON...

397.08K€ | Participante

H. LEE MOFFITT CANCER CENTER...

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BRCAstem Monitoring cancer stem cell dynamics and therapeutic respons... 225K€ Cerrado

TargetBRCA To develop a new targeted therapy for the treatment of naive... 150K€ Cerrado

DDRESPONSE The DNA damage response and breast cancer 8M€ Cerrado

SAF2014-57680-R PROFUNDIZANDO EN EL MECANISMO DE ACCION DE LOS INHIBIDORES D... 97K€ Cerrado

SYNvia Exploring synthetic lethality and synthetic viability to... 238K€ Cerrado

DynaCOMP Assessing compounds targeting DNA replication licensing comp... 150K€ Cerrado

Duración del proyecto: 57 meses Fecha Inicio: 2019-03-27
Fecha Fin: 2023-12-30

Líder del proyecto

CONSIGLIO NAZIONALE DELLE RICERCHE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 251K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Inhibition of PARP1 in cancer therapy is a recently adopted strategy to treat cancers where DNA repair is defective, such as breast and ovarian cancer caused by mutations in BRCA1 or BRCA2. In addition, PARP1 inhibitors (PARPi) can be useful even in the absence of BRCA mutations, likely due to pathogenic variants or epigenetic inactivation of other DNA repair related genes. However, development of resistance to PARPi is a significant challenge. To address this challenge, I propose to identify proteins that modulate PARP1 activity that could be used as additional therapeutic targets. The strength of this project is based on a systems biology overall strategy exploiting multiple independent datasets to identify candidates protein interactors, followed by a rigorous biochemical and genetic approach to characterize this interaction. Analysis of identified proteins and their role in PARPi resistance will be achieved at three main levels: a) in-silico and molecular studies of the interaction; b) influence on PARP1 activity and role in PARPi resistance after CRISPR-cas9 editing; c) expression levels in breast and ovarian cancer tissues. Results from this project will illuminate mechanisms of PARPi resistance and generate potential targets for therapy in breast and ovarian cancer. These results will contribute to the reduction in mortality due to breast and ovarian cancer and they will give an answer to this world-wide diffuse challenge.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores